In the latest NICE guidance published in, Repatha failed to get praise managers. The reason for this is due to two things. First, the existing data from clinical studies failed to demonstrate its efficacy. Although Repatha in reducing bad cholesterol remarkable achievements,
but there is no evidence that these cholesterol levels by lowering the
risk of the user can reduce angina, heart disease.
In
addition, some analytical methods Repatha NICE also been questioned,
for example, in the study Amgen researchers used the Framingham
assessment criteria rather than NICE recommended to analyze the efficacy of the drug. Therefore, managers also need to wait until the second half of 2016 in order to lower the effect of conclusion. Secondly, PCSK9 drugs a listing of its high price, let everyone stunned. Patients need to pay £ 4,448.60 (140mg receiving treatment every two
weeks) or £ 6,123.60 (420mg receiving monthly treatment), the high price
for NICE unacceptable.
In fact, PCSK9 price issue has so many people criticized. Whether
Repatha or Sanofi / regeneration yuan's Repatha are so patient and kind
of health insurance companies to be "robbed" feeling. In the US, the pricing of these two drugs were $ 14,100 / year and $ 14,600 / year. The estimated non-profit organization Institute for Clinical and
Economic Review, the reasonable price range of these two drugs should be
between $ 3,615- $ 4,811.
Although Amgen is working with various aspects Repatha approached in terms of price, but it is clear that companies also need to show more sincerity.
( Bolise Co., Ltd. www.chemicalspharm.com )
没有评论:
发表评论